Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients

The amino acid sequence of the M-protein for multiple myeloma is unique compared to polyclonal antibodies in patients’ blood. This uniqueness exploited develop an ultrasensitive detection method utilizing mass spectrometry (MS). involves de novo sequencing full-length M-protein, and a targeted MS/MS assay detect quantify serum samples. Healthy control spiked with NISTmAb serial samples from MM patient were used demonstrate ability platform monitor target M-protein. protein obtained matched published sequence, confirming accurately serum. was quantified down 0.0002 g/dL serum, level hundreds times more sensitive than conventional blood-based tests such as SPEP IFE. sample could be throughout complete remission, demonstrating utility track considerably beyond sensitivities current tests. Notably, detected 2-fold rise levels 10 months before any changes by MS-based highly sensitive, noninvasive, requires only small amount less 100 μL. Sequencing data deposited into PRIDE identifier PXD022784, quantification can found Panorama Public PXD022980.